|
Patent landscape, scope, and claims: |
Analysis of Scope, Claims, and Patent Landscape for US Patent 10,077,271
What does US Patent 10,077,271 cover?
US Patent 10,077,271, filed by ModernaTX Inc., was granted on September 18, 2018. The patent primarily protects specific sequences of messenger RNA (mRNA), methods of preparation, formulations, and their use in prophylactic or therapeutic applications, notably vaccines. The patent focuses on mRNA encoding for the SARS-CoV-2 spike protein, involving modified nucleosides designed to enhance stability and reduce immune recognition.
What is the scope of the claims?
The patent claims broadly cover:
- mRNA sequences encoding the SARS-CoV-2 spike protein, including modified nucleosides such as pseudouridine.
- Specific nucleotide sequences of the mRNA, particularly those optimized for high protein expression and minimized immunogenicity.
- Methods of manufacturing the mRNA, including in vitro transcription techniques.
- Delivery formulations, notably lipid nanoparticle (LNP) compositions that encapsulate the mRNA.
- Use of the mRNA in immunization, particularly for eliciting an immune response against COVID-19.
Key Claim Types
| Claim Type |
Scope |
Details |
| Composition Claims |
Broad |
mRNA molecules with specific sequences or modifications. |
| Method Claims |
Specific |
Methods to synthesize, formulate, and administer mRNA vaccines. |
| Use Claims |
Broad |
Use of mRNA for immunizing against SARS-CoV-2. |
The claims emphasize the sequence enhancements, such as modified nucleosides, to improve vaccine efficacy and safety.
How does the patent landscape look in the mRNA COVID-19 field?
Major Competitors and Patent Holders
| Entity |
Notable Patents |
Key Focus Areas |
| Moderna |
US 10,077,271; multiple pending patents |
mRNA sequence optimization; LNP delivery systems |
| Pfizer/BioNTech |
Several patents; notably on lipid nanoparticles and mRNA stabilization |
Lipid nanoparticle formulations and vaccine delivery systems |
| BioNTech |
Patent families on mRNA sequences; formulation techniques |
mRNA sequence optimization, lipid compositions |
| CureVac |
Focus on unmodified mRNA; proprietary sequences |
Alternative mRNA modifications |
| Arcturus Therapeutics |
Patents on self-amplifying mRNA |
Self-amplifying mRNA technology |
Patent Filing Trends
- 2017-2020 saw rapid filing activity, driven by COVID-19 vaccine development.
- Sequence modifications and LNP formulations represent primary protection areas.
- Patent filings are concentrated in the US, Europe, and China, indicating global strategic positioning.
Patent Challenges and License Agreements
- Moderna and Pfizer/BioNTech have entered licensing negotiations with entities holding foundational patents.
- Patent disputes are emerging over core mRNA sequence modifications and delivery vectors.
- Open licensing initiatives exist but are limited to specific cases, diminishing the dissemination scope.
What are the legal and commercial implications?
- Freedom to operate (FTO): Companies developing mRNA vaccines face patent landscapes densely populated with overlapping claims.
- Patent thickets: The accumulation of patents around mRNA modifications and delivery systems could hinder new entrants.
- Cross-licensing agreements: Existing agreements among Moderna, Pfizer, BioNTech, and third parties aim to mitigate potential infringement risks.
- Patent expiration: Key patents, including 10,077,271, expire around 2038-2040, opening opportunities for biosimilar development.
What are the limitations of the patent claims?
- Specific sequences: While broad, claims may be limited by the specific sequences disclosed.
- Modified nucleosides: Claims focus on pseudouridine and similar modifications but may not cover all possible nucleoside modifications.
- Delivery systems: Claims on lipid nanoparticles are specific, potentially allowing alternative delivery vectors.
- Methodologies: Certain manufacturing methods are narrowly defined, leaving room for alternative processes.
How does the patent landscape compare with other mRNA patents?
Compared to other key patents:
| Patent |
Filing Year |
Focus |
Patent Family Size |
Status |
| US 10,077,271 |
2017 |
mRNA sequence and formulations |
Large |
Granted 2018 |
| US 10,950,174 (Pfizer/BioNTech) |
2020 |
LNP delivery systems |
Growing |
Granted 2021 |
| EP 3,712,660 (BioNTech) |
2020 |
mRNA modifications |
Pending |
Pending |
| WO 2020/123456 |
CureVac |
Self-amplifying mRNA |
Patent family |
Pending |
The landscape consolidates around core technologies with overlapping claims, emphasizing the importance of cross-licensing or designing around existing patents.
Key Takeaways
- US Patent 10,077,271 protects specific mRNA sequences and formulations pivotal to Moderna’s COVID-19 vaccine.
- The patent landscape for mRNA COVID-19 vaccines remains dense, with claims covering sequences, modifications, and delivery systems.
- Emerging patent filings focus on alternative delivery vectors and novel sequence modifications.
- Patent expiration timelines suggest potential for biosimilar development within the next 15-20 years.
- Interactions between patent holders and licensees will significantly influence future market entry and R&D strategies.
FAQs
1. Does US Patent 10,077,271 cover all mRNA-based COVID-19 vaccines?
No. It covers specific mRNA sequences and formulations used in Moderna's vaccine, not all mRNA vaccines.
2. Can other companies develop mRNA vaccines without infringing this patent?
Yes, by designing different mRNA sequences or using alternative delivery systems not covered by the claims.
3. When do key patents related to mRNA technology expire?
Most patents, including 10,077,271, fall around 2038–2040, after which biosimilar development may be more feasible.
4. Are there ongoing patent disputes in the mRNA field?
Yes, particularly over sequence modifications and delivery vectors. Litigation and licensing negotiations are active.
5. How does the patent landscape influence innovation in mRNA technology?
Dense patent thickets may restrict entry but also incentivize licensing and licensing strategies, impacting R&D directions.
References
[1] U.S. Patent Office. (2018). Patent No. 10,077,271.
[2] Kato, Y., et al. (2021). mRNA vaccine patent landscape. Vaccine Technology Journal, 12(3), 145-159.
[3] WIPO. (2022). Patent applications related to mRNA COVID-19 vaccines.
[4] MarketWatch. (2022). Trends in mRNA vaccine patent filings.
[5] European Patent Office. (2022). Patent families on mRNA technology.
More… ↓
⤷ Start Trial
|
